Intravitreal Enzyme Replacement Therapy Slows Retinopathy in Late Infantile Ceroid Lipofuscinosis Type 2
Neuropediatrics · 01.04.2025 · 56 (02) · 142-146
DOI: 10.1055/a-2510-5592 ↗Kurz gefasst
Fallbericht in der Zeitschrift Neuropediatrics, erschienen am 01.04.2025. Verfasst von Claudia S Priglinger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, LMU University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany. Hauptthemen laut MEDLINE: Neuronal Ceroid-Lipofuscinoses, Enzyme Replacement Therapy, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Aminopeptidases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Ceroid lipofuscinosis type 2 (CLN2) is caused by biallelic pathogenic variants in the TPP1 gene, encoding lysosomal tripeptidyl peptidase 1 (TPP1). The classical late-infantile phenotype has an age of onset between 2 and 4 years and is characterized by psychomotor regression, myoclonus, ataxia, blindness, and shortened life expectancy. Vision loss occurs due to retinal degeneration, usually when severe neurological symptoms are already evident. Intracerebroventricular enzyme replacement therapy (ICV-ERT) using recombinant human TPP1 (rhTPP-1) was shown to slow the neurological decline; however, it does not prevent loss of vision. Intravitreal rhTPP-1 (IVT-ERT) was described to halt retinal degeneration in a canine CLN2 model and a compassionate-use study in humans. We report on the clinical and ophthalmological outcome in an early-treated patient homozygous for a pathogenic variant in TPP1 known to be associated with severe CLN2 retinopathy. He was started on ICV-ERT at the age of 40 months and 4 weekly IVT-ERT in one eye at the age of 60 months. The other eye served as untreated control. Baseline best corrected visual acuity (BCVA) was 0.5 with mild bull's eye maculopathy evident in both eyes. After 24 months of IVT-ERT, BCVA in the treated eye was 0.2 with bull's eye maculopathy sparing outer retinal layers, whereas the untreated eye had progressed to endstage retinopathy and BCVA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, LMU University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
- Folkhälsan Research Center, Helsinki, Finland.
- Department of Inborn Errors of Metabolism, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
- Department of Anesthesiology, LMU University Hospital, Ludwig-Maximilians-University Munich, Germany.
- Department of Pharmacy, LMU University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
- Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Zitieren
APA
Priglinger, C. S., Courage, C., Lotz-Havla, A. S., Gerhardt, M., Ehrt, O., Kurz, M., Pudritz, H., Rudolph, G., Jackson, C. B., & Maier, E. M. (2025). Intravitreal Enzyme Replacement Therapy Slows Retinopathy in Late Infantile Ceroid Lipofuscinosis Type 2. Neuropediatrics, 56(02), 142-146. https://doi.org/10.1055/a-2510-5592
Vancouver
Priglinger CS, Courage C, Lotz-Havla AS, Gerhardt M, Ehrt O, Kurz M, et al. Intravitreal Enzyme Replacement Therapy Slows Retinopathy in Late Infantile Ceroid Lipofuscinosis Type 2. Neuropediatrics. 2025;56(02):142-146. doi:10.1055/a-2510-5592
BibTeX
@article{Priglinger2025,
author = {Priglinger, Claudia S and Courage, Carolina and Lotz-Havla, Amelie S and Gerhardt, Maximilian and Ehrt, Oliver and Kurz, Matthias and Pudritz, Harald and Rudolph, Günther and Jackson, Christopher B and Maier, Esther M},
title = {Intravitreal Enzyme Replacement Therapy Slows Retinopathy in Late Infantile Ceroid Lipofuscinosis Type 2},
journal = {Neuropediatrics},
year = {2025},
volume = {56},
number = {02},
pages = {142--146},
doi = {10.1055/a-2510-5592}
}
EUVIMED